Business
Remepy, Merck KGaA collaborate on hybrid drugs combined with AI-personalized digital therapeutics
Remepy, a New York-based digital health startup, has entered a hybrid drugs collaboration with Merck KGaA (FRA: MRK.DE; OTC: MKKGY), Darmstadt, Germany, to...
Roche's Q1'26 Earnings Call: Obesity dual agonist advances as giredestrant filed in adjuvant setting
Roche's Q1 2026 earnings conference call, held April 23, 2026, centered on three converging pipeline signals: an imminent fenebrutinib NDA filing carrying...
Sanofi's Q1'26 Earnings Call Highlights: Lunsekimig a new respiratory priority, amlitelimab safety profile defended
Sanofi signaled a strategic pivot toward lunsekimig as its next respiratory franchise asset while defending amlitelimab's path to regulatory submission...
Eli Lilly acquires Ajax Therapeutics for USD 2.3b targeting myeloproliferative neoplasm treatments
Eli Lilly (NYSE: LLY) has agreed to acquire US-based Ajax Therapeutics, a private New York-incorporated biopharmaceutical company, for up to USD 2.3 billion...
Sun Pharma acquires Organon for USD 11.75b, expanding Women's Health and biosimilars portfolio
India-based Sun Pharmaceutical Industries Limited (Reuters: SUN.BO | NSE: SUNPHARMA | BSE: 524715) has entered into a definitive agreement to acquire...
Maze Therapeutics prices USD 150m public offering for kidney and metabolic disease programs
Maze Therapeutics (NASDAQ: MAZE), a clinical-stage biopharmaceutical company based in South San Francisco focused on kidney and metabolic diseases, has...
Cumberland Pharmaceuticals divests branded portfolio to Apotex for USD 100m, refocuses on orphan drugs
Cumberland Pharmaceuticals (Nasdaq: CPIX) has entered into a definitive agreement to divest its branded commercial pharmaceutical portfolio to Canada-based...
Atrium Therapeutics earns USD 15m milestone from Bristol Myers Squibb CVD collaboration
Atrium Therapeutics (Nasdaq: RNA) has earned a USD 15 million development milestone from Bristol Myers Squibb (NYSE: BMY) under their global cardiovascular...
Ferrosa Therapeutics closes USD 3.5m seed round for bispecific anemia inflammation antibody
Ferrosa Therapeutics AG, a Basel, Switzerland-based biotechnology company developing a bispecific antibody for anemia of inflammation, has closed a USD 3.5...
Servier completes USD 2.5b acquisition of Day One Bio for pediatric glioma asset Ojemda
France-based Servier has completed the acquisition of US-based Day One Biopharmaceuticals (Nasdaq: DAWN) via a tender offer at USD 21.50 per share,...
Eli Lilly fully backs out of USD 960m ocadusertib collaboration with Rigel
Eli Lilly and Company (NYSE: LLY) has notified Rigel Pharmaceuticals (NASDAQ: RIGL) of its election to terminate a License and Collaboration Agreement...
Ray Therapeutics raises USD 125m Series B for optogenetic gene therapy programs
Ray Therapeutics, a Berkeley, California-based clinical-stage biopharmaceutical company developing optogenetic gene therapies for retinal degenerative...
GSK acquires pulmonary hypertension biotech 35Pharma for USD 950m, gaining HS235 asset
GSK (LSE/NYSE: GSK) has completed the acquisition of Canada-based 35Pharma Inc., a private clinical-stage biopharmaceutical company, for USD 950 million in...
Elicera Therapeutics raises SEK 72.8m in rights issue for clinical trials
Sweden-based Elicera Therapeutics AB (Nasdaq First North Growth Market: ELIC) announced a rights issue of approximately SEK 72.8 million, structured to fund...
Nektar Therapeutics raises USD 250m in underwritten public offering
San Francisco-based Nektar Therapeutics (Nasdaq: NKTR) announced on April 20, 2026, an underwritten public offering of USD 250 million in common stock and...
The AllSci Brief
Systematic R&D and deal news. Daily.